Skip to content
Biotechnology, Environment

EcoPHA Biotech Unveils World-First PHA Breakthrough at FEMS MICRO 2025 in Milan

EcoPHA Biotech 2 mins read

EcoPHA Biotech Unveils World-First PHA Breakthrough at FEMS MICRO 2025
Australian innovation uses Pongamia oil to produce scalable, marine-safe bioplastics

Milan / Sydney – 29 July 2025
Australian biotech leader EcoPHA has unveiled a major scientific breakthrough at FEMS MICRO 2025, one of the world’s foremost conferences in microbiology and environmental innovation, held this week in Milan, Italy.

EcoPHA’s Chief Technology Officer, Dr Long Nguyen, presented the company’s latest advancement: the use of Pongamia oil, a carbon-sequestering, non-edible crop grown on marginal land, as a novel, sustainable feedstock for the production of PHB, a fully biodegradable member of the PHA bioplastics family.

This pioneering development has already resulted in a PCT patent filing, firmly positioning Ecopha at the forefront of next-generation bioplastics powered by low-cost, renewable, and climate-resilient inputs.

“We’re excited to unveil our breakthrough in converting Pongamia oil into PHA bioplastics — a solution that combines environmental impact with scientific innovation,” said Dr. Wilson Ling, CEO and Co-Founder of EcoPHA Biotech. “Filing our PCT patent is a major step forward for us, and it was a great honour to present our capability and vision at FEMS MICRO 2025. This recognition motivates us to keep pushing the boundaries of sustainable materials to help save the world.”

As governments and industries race to reduce plastic pollution, EcoPHA’s breakthrough arrives at a critical moment. Unlike many so-called ‘compostable’ alternatives, PHA biodegrades naturally in soil, water and marine environments, without leaving toxic residue or microplastics, and without requiring industrial composting.

Dr Nguyen’s presentation formed part of a broader global dialogue on microbiology-driven climate solutions, including circular economy transformation and the role of microbial innovation in achieving true sustainability. The event brought together leading scientists, policymakers and innovators from Europe, North America, and the Asia-Pacific.

EcoPHA’s work represents a new frontier in nature-aligned materials science, offering a viable, scalable alternative to petrochemical plastics while leveraging Australia’s unique natural resources and biotechnology expertise.

We extend our sincere thanks to FEMS MICRO 2025 for the platform to share, connect, and lead with purpose.


Key Facts:
    • Organisation: EcoPHA Biotech

    • Location of Event: Milan, Italy

    • Event: FEMS MICRO 2025 – Federation of European Microbiological Societies Congress

    • Date of Announcement: 29 July 2025

    • Presented by: Dr Long Nguyen, Chief Technology Officer, EcoPHA Biotech

    • Breakthrough: Use of Pongamia oil, a carbon-sequestering, non-edible crop, as a novel feedstock for producing PHB, a fully biodegradable PHA bioplastic

    • Significance:

      • PHB produced using Pongamia oil biodegrades in soil, water and marine environments - without industrial composting

      • The development addresses the urgent global need for scalable, plastic-free, marine-safe packaging solutions

      • A PCT patent has been filed for the production process

    • Impact: Positions EcoPHA as a global leader in microbiology-led sustainable materials science

    • Recognition: Presented as part of the official scientific program at one of the world’s premier microbiology and environmental sustainability forums


About us:

EcoPHA Biotech is an Australian biotechnology company pioneering the development of scalable, marine-safe PHA bioplastics using low-cost, renewable feedstocks. By harnessing microbial innovation and sustainable agriculture, Ecopha creates fully biodegradable materials that break down naturally in soil, water, and marine environments, without industrial composting or leaving microplastic residue.

With a strong focus on scientific excellence, EcoPHA is committed to accelerating the global transition away from petrochemical plastics and shaping a circular, climate-resilient future through nature-aligned materials innovation.


Contact details:

CMO / EcoPHA Biotech

[email protected]

Media

More from this category

  • Environment, Transport Automotive
  • 12/12/2025
  • 14:27
NALSPA

Electric Car Discount review must drive clean energy transition and cost-of-living relief

The National Automotive Leasing and Salary Packaging Association (NALSPA) has today welcomed the federal government’s announcement of the statutory review of the Electric Car Discount, noting that the policy continues to be highly effective in encouraging Australians to make the switch to cleaner cars.The federal government announced today that next year it will review the Electric Car Discount, otherwise known as the EV FBT exemption which came into effect in July 2022.The review will consider the operation of the Electric Car Discount over the first three years it has been in place, as required by the legislation.“We will actively participate…

  • Biotechnology
  • 12/12/2025
  • 11:40
4DMedical Limited (ASX:4DX)

4DMedical secures $30.2 million with options underwrite

Highlights• $30.2 million in funding secured by entering into an underwriting agreement that ensures the exercise of all the 4DXO listed options• Additional funding results in a proforma cash balance as at 30 September 2025 of $63.7 million • 4DMedical is experiencing unprecedented interest in CT:VQ™, with multiple contract discussions underway, positioning CY26 as a transformational year Melbourne, Australia, 12 December 2025: 4DMedical Limited (ASX: 4DX, “4DMedical” or the “Company”) today announces it has entered into an option underwriting agreement (Underwriting Agreement) with Bell Potter Securities Limited (Underwriter) to fully underwrite the exercise of the 4DXO listed options on issue,…

  • Biotechnology
  • 12/12/2025
  • 10:58
EBR Systems, Inc. (ASX:EBR)

First implant in the Totally Leadless CRT (TLC-AU) Study

Key Highlights • First patient enrolment and implant in the Totally Leadless CRT (TLC-AU) study by Dr Paul Gould from the Princess Alexandra Hospital, Brisbane • TLC-AU is a feasibility study into using the WiSE® System alongside a leadless pacemaker to achieve totally leadless CRT • The study represents a significant strategic milestone as EBR evaluates WiSE as a potential first-line therapy for treating newly diagnosed heart failure patients • TLC-AU could meaningfully expand EBR’s addressable market Sunnyvale, California; 12 December 2025: EBR Systems, Inc., developer of the world’s only wireless cardiac pacing device for heart failure, announces the first…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.